Equity Residential vs AbbVie

Side-by-side comparison of AI visibility scores, market position, and capabilities

AbbVie leads in AI visibility (90 vs 68)

Equity Residential

LeaderReal Estate & Property Tech

Enterprise

Chicago apartment REIT (NYSE: EQR) ~80,000 apartments; Q4 2024 EPS $1.10 (+34%), same-store NOI +3.1% in 2024, 2025 guidance 2.25-3.25% rev growth in Boston/NYC/Seattle/SF competing with AvalonBay.

AI VisibilityBeta
Overall Score
B68
Category Rank
#45 of 290
AI Consensus
55%
Trend
stable
Per Platform
ChatGPT
62
Perplexity
67
Gemini
74

About

Equity Residential is a Chicago, Illinois-based apartment real estate investment trust — publicly traded on the New York Stock Exchange (NYSE: EQR) as an S&P 500 Real Estate component and member of the S&P 500 — owning and operating approximately 300 apartment communities with roughly 80,000 apartments concentrated in high-barrier-to-entry coastal and Sun Belt urban markets including Boston, New York, Washington D.C., Seattle, San Francisco Bay Area, Los Angeles, Denver, Atlanta, and Dallas through approximately 2,400 employees. In Q4 2024, Equity Residential reported earnings per share of $1.10 (versus $0.82 in Q4 2023, +34.1%), with full year 2024 same-store revenues increasing 3.0% and same-store net operating income (NOI) growing 3.1%. For 2025, the company provided guidance of 2.25%-3.25% same-store revenue growth, reflecting continued but moderating rent increases across its coastal and Sun Belt markets. Founded in 1966 by Sam Zell (who also founded Equity Commonwealth and other real estate enterprises), Equity Residential went public in 1993 and is managed by CEO Mark Parrell, who joined from Heitman Capital Management. The company's portfolio of professionally managed, amenity-rich apartment communities targets the affluent renter demographic — typically college-educated professionals earning $90,000-150,000 annually — who choose to rent in high-cost gateway cities rather than purchase.

Full profile

AbbVie

LeaderHealthcare

General

Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.

AI VisibilityBeta
Overall Score
A90
Category Rank
#9 of 1167
AI Consensus
60%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
99
Gemini
83

About

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.

Full profile

AI Visibility Head-to-Head

68
Overall Score
90
#45
Category Rank
#9
55
AI Consensus
60
stable
Trend
stable
62
ChatGPT
99
67
Perplexity
99
74
Gemini
83
61
Claude
96
78
Grok
95

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.